Insider files to sell 1,942 common shares

Form 144 discloses a planned sale of restricted or control securities.

Rhea-AI Filing Summary

Form 144 discloses a planned sale of restricted or control securities. The filer intends to sell 1,942 shares of common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $30,334.04. The filing notes that 26,820,000 shares of this class were outstanding.

The securities to be sold were acquired as a grant from the issuer on 01/13/2026, with a stated amount of 6,469 shares and a cash payment date of 01/14/2026. The notice also reports that David Krempa sold 6,264 common shares on 12/12/2025 for gross proceeds of $106,460.00. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ETON Form 144 filing disclose?

It discloses a planned sale of 1,942 shares of common stock with an aggregate market value of $30,334.04 under Rule 144.

Who is the broker for the planned ETON share sale?

The planned sale will be executed through Raymond James & Associates, located at 880 Carillon Parkway, St. Petersburg, FL 33716.

On which exchange are the ETON shares expected to be sold?

The Form 144 states that the common shares are expected to be sold on the NASDAQ exchange.

How many ETON shares are outstanding according to this notice?

The notice reports that there are 26,820,000 shares of the common stock class outstanding.

How and when were the ETON shares to be sold acquired?

The 6,469 common shares referenced in the acquisition table were acquired on 01/13/2026 via a grant from the issuer, with cash payment dated 01/14/2026.

What prior ETON share sales are reported in the last 3 months?

The filing reports that David Krempa sold 6,264 common shares on 12/12/2025 for gross proceeds of $106,460.00.

What representation does the seller make in this Form 144?

The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 05:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001968254
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	Krempa David
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	1942	30334.04	26820000	01/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/13/2026	Grant	Issuer			6469	01/14/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Krempa 5865 Yuma Ln N Minneapolis MN 55446	Common	12/12/2025	6264	106460.00

144: Remarks and Signature

Remarks	Sell to cover taxes on grant
Date of Notice	01/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Maressia Rooks-Bailey, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for David Charles Krempa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)